Results 121 to 130 of about 29,860 (191)

Macrolide-resistant <i>Mycobacterium avium</i> complex pulmonary disease: A narrative review. [PDF]

J Clin Tuberc Other Mycobact Dis
Cumar Y, Forsman LD, Schön T, Wejse C, Dahl VN.   +4 more
europepmc   +1 more source

Cost-effectiveness of BPaL-based and 9-month modified all-oral short treatment regimens for rifampicin-resistant tuberculosis in Belarus. [PDF]

PLOS Glob Public Health
Yatskevich N.
europepmc   +1 more source

Implementing shorter all-oral treatment durations for multidrug-resistant tuberculosis in the UK: from concept to application. [PDF]

BMJ Open Respir Res
Chavda A, Gilchrist M, Capstick T, Chen C, Kon OM.   +4 more
europepmc   +1 more source

Cerebral and bone multidrug resistant tuberculosis treated with the BPaLM regimen: case report. [PDF]

Front Pharmacol
Calamelli M, Davoli C, Gerami R, Gulletta M, Lovatti S, Pavesi A, Rossi B, Matteelli A.   +7 more
europepmc   +1 more source

Socio-ecological vulnerability subgroups predict adherence and treatment outcomes in multidrug-resistant tuberculosis and HIV: a latent class analysis. [PDF]

BMC Infect Dis
Guzman KJ, Wolf A, Perumal R, Lu X, Boodhram R, Seepamore B, Reis K, Amico KR, Friedland G, Zelnick JR, Daftary A, Cummings M, Padayatchi N, Naidoo K, O'Donnell M.   +14 more
europepmc   +1 more source

Outcomes and Treatment-limiting Adverse Events of Patients Receiving BPaL and BPaL-FQ in California. [PDF]

Open Forum Infect Dis
Katrak SS, Wang RC, Keh CE, Nabity SA, Okada RC, Raftery A, Wendorf KA, Agraz-Lara R, Chakrabarty M, Chevinsky JR, Chitnis AS, Dasgupta-Tsinikas S, Goozé L, Kadakia A, Kaiser C, Louie JK, Morgan J, Nguyen TD, Percak J, Polesky AH, Radner A, Sahni H, Sreenivasan M, Sherrick R, Soukup JD, Waterman C, Yeturu P, Yu S, Barry PM.   +28 more
europepmc   +1 more source

No phenotypic resistance observed for most group-3 and -4 variants in <i>Mycobacterium tuberculosis</i> genes related to bedaquiline, clofazimine, delamanid, and pretomanid in a Central and West African context. [PDF]

Microbiol Spectr
Massou F, Dewaele K, Gnamy A, Balde R, Mulders W, Mehan CJ, de Jong BC, Affolabi D, Tzfadia O, Rigouts L.   +9 more
europepmc   +1 more source

Bedaquiline resistance: a predictable consequence of a game-changing drug? [PDF]

ASM Case Rep
Lubelchek R.
europepmc   +1 more source

<i>In vitro</i> characterization of GSK2556286 in combination with bedaquiline and pretomanid against <i>Mycobacterium tuberculosis</i>. [PDF]

Antimicrob Agents Chemother
Rabodoarivelo MS, Galizia J, Recchia D, Stamilla A, Dal Molin M, Hoffmann E, Gaudin C, Eveque M, Ndjogou D, Bailo R, Leding AAM, Simonsson USH, Sanz O, Jiménez E, Bates RH, Degiacomi G, Lucía A, Willand N, Baulard A, Rybniker J, Pasca MR, Ramón-García S, ERA4TB consortium.   +22 more
europepmc   +1 more source